Category Archives: Tekturna

Featured Stories
Birth Control Shot Depo-Provera may Increase HIV Risk

Birth Control Shot Depo-Provera may Increase HIV Risk, Study Suggests

A new study has linked the use of Depo-Provera (medroxyprogesterone acetate), an injectable type of birth control, to an increased risk of HIV infection.

Read More

Canadian Warning Issued for Actos Bladder Cancer Side Effect Risk

Health Canada has become the most recent national drug regulator to issue a warning about Actos and bladder cancer. Last month, the agency warned that interim results from a 10-year-study indicated that patients taking Actos for more than a year faced an increased risk of bladder cancer. Health Canada also ...

Read More

Fracking Releasing Hazardous Chemicals into Local Waterways

Fracking Releasing Hazardous Chemicals into Local Waterways

Study shows two hazardous chemicals—ammonium & iodide—are being released & spilled into Pennsylvania and W.Virginia waterways from fracking operations in Marcellus shale.

Read More

System for Tracking Prescription Drug Side Effects Flawed

Study Finds System for Tracking Prescription Drug Side Effects Flawed

System for keeping track of dangerous side effects of prescription drugs is flawed because drug makers are submitting incomplete information about problems to the FDA.

Read More

Canadian Study Finds Actos Raises Bladder Cancer Risk by 22 Percent

Yet another study is confirming the association between the diabetes drug, Actos, and bladder cancer. This latest research, published today in the Canadian Medical Association Journal, found that taking Actos raised the risk of bladder cancer among diabetics by about one-fifth.

Read More

Older Patients Face Heart Attack Risk Following Surgery

Older Hip Implant, Knee Replacement Patients Face Heart Attack Risk Following Surgery

An emerging report reveals that older hip implant and knee replacement patients face increased heart attack risks following surgery. The risk for acute myocardial infarction (AMI) was seen in the first two weeks after these surgical procedures.

Read More

Cancer Groups Call for E-cigarettes Regulation/Research

Two-Leading-Cancer-Groups-Issue-Call-for-Regulation-of-E-cigarettes-and-Research-on-Health-Risks

The American Society of Clinical Oncology & the American Association for Cancer Research called for government regulation & research of e-cigarettes on health effects.

Read More

FDA Advisory Panel Wrestling with Metal-on-Metal Hip Replacement Safety

An advisory panel for the U.S. Food & Drug Administration (FDA) began a highly-anticipated meeting yesterday to discuss the safety of metal-on-metal hip implants. Among other things, the panel of outside experts is being asked to make recommendations regarding the best practices for monitoring patients with metal-on-metal hip replacements. ...

Read More

Three Injured, Long Island Railroad Train Hits Car on Tracks

Three Injured When Long Island Railroad Train Hits Car on Tracks

3 people, injured on Wednesday at 1:20 p.m. when a LIRR train hit a livery cab on the tracks west of Wyandanch station. The train engineer, who suffered a shoulder injury.

Read More

Knee Replacement Patients Should Consider Nickel Allergies before Surgery

Individuals considering undergoing knee replacement surgery should ask their doctors to run a test to determine if they have a nickel allergy. Determining if a patient suffers from a nickel allergy will ensure the right knee implant is chosen for their surgery, and possibly save them from considerable pain and ...

Read More

Drug Maker, Novartis, Accused Again of Kickback Schemes

We have long noted that the financial relationships between the drug and the health care industries have led to enormous controversy. Critics maintain that such relationships create conflicts of interest and could unduly influence everything from research findings to prescribing … Continue reading

Posted in Consumer Fraud, Legal News, Pharmaceuticals, Tekturna |

U.S. Prosecutors Investigating Novartis Marketing of Blood Pressure Drug Tekturna

U.S. prosecutors are investigating European drug manufacturer Novartis for its marketing of products including hypertension drug Tekturna. In a recent regulatory filing, Swiss-based Novartis revealed that, last year, a U.S. unit of the company received a subpoena from federal prosecutors … Continue reading

Posted in Health Concerns, Legal News, Pharmaceuticals, Tekturna |

Analysis of adverse event reports questions benefit of blood pressure drug Tekturna

A recent analysis of adverse health events linked to certain prescription drugs identified 100 incidents linked to the blood pressure medication Tekturna in just the first part of this year. The Institute for Safe Medication Practices (ISMP) combed a database … Continue reading

Posted in Pharmaceuticals, Tekturna | Tagged |

Tekturna Linked to Significant Number of Adverse Events

Independent watchdog group, the Institute for Safe Medical Practices (ISMP) reports a 90 percent increase in significant adverse drug event reports received by the U.S. Food & Drug Administration (FDA) over the past four years. Among these, are events associated … Continue reading

Posted in Pharmaceuticals, Tekturna |

Tekturna Label Changes, Valturna Market Withdrawal Announced by Novartis

Novartis announced yesterday that the label for the blood pressure drug Tekturna (aliskiren) will be updated with new warnings regarding its use in people with diabetes and kidney problems. Novartis also announced it will no longer market Valturna, a single-pill … Continue reading

Posted in Pharmaceuticals, Tekturna | Tagged |

Tekturna (Aliskiren) Associated with Serious Side Effects, Including Stroke, Severe Kidney Damage

Tekturna (aliskiren) and other medications containing aliskiren have been associated with serious side effects, including non-fatal stroke and severe kidney damage, in some patients. Tekturna and other aliskiren products were recently the subject of safety warnings in Europe (where it … Continue reading

Posted in Pharmaceuticals, Tekturna | Tagged |

MHRA Issues New Contraindications, Recommendations for Rasilez (Aliskiren) with ACE Inhibitors, ARBs

Health regulators in the U.K. have announced new contraindications and warnings regarding Rasilez (aliskiren), a blood pressure drug which is sold as Tekturna in the U.S. According a Drug Safety Update issued by the Medicine and Healthcare Products Regulatory Agency, … Continue reading

Posted in Pharmaceuticals, Tekturna |

Novartis Updates Rasilez Label in Europe with New Warnings for Diabetes, Kidney Patients

The blood pressure drug Rasilez – sold in the U.S. under the brand name Tekturna – will soon bear new safety warnings on its European label, after a clinical trial was halted because subject patients experienced a high rate of … Continue reading

Posted in Pharmaceuticals, Tekturna |

Canada Issues Warning, Updates Labeling For Rasilez

Canada just issued a warning for Rasilez, a high blood pressure drug known as Tekturna in the United States. Novartis Pharmaceuticals, Canada Inc makes Rasilez. Health Canada and Novartis issued the warning for aliskiren-containing products, Rasilez and Rasilez HCT, after … Continue reading

Posted in Pharmaceuticals, Tekturna |

Tekturna To Undergo Canadian Safety Review

High blood pressure drug, Tekturna, will undergo a Canadian Safety Review after a clinical study was halted by drug maker, Novartis, over unexpected adverse reactions. “Specifically, when used in combination with other blood pressure-lowering drugs known as angiotensin-converting enzyme (ACE) … Continue reading

Posted in Tekturna |

© 2005-2017 Parker Waichman LLP ®. All Rights Reserved.